



Models are for illustrative purposes only.

NovoSecure™ Overview Guide

Assisting patients through the
reimbursement period and beyond

NovoSecure™



Liam lives with hemophilia A.

Table of Contents

Introduction

3-4

NovoSecure™ Overview



Process Flow & Services

Therapy Preparation

5-12



Benefits Verification

- QuickCheck™
- Statement of Medical Necessity



Insurance Coordination

- Prior Authorizations
- Supporting Documentation
- Appeals



Product Support Eligibility

- Co-pay Assistance Program
- Product Assistance Program

Starting Therapy

13



Patient Resources

- Interim Product Program

During Therapy

14-17



NovoSecure™ Specialist Support

- Patient Reauthorization
- Phone Support



Patient Lifestyle Support

- Helping Patients Manage Their Lives With Hemophilia
- Fostering Personal Growth



Community

- Helping Patients Connect

NovoSecure™



NovoSecure™ Overview

NovoSecure™ is a comprehensive support program designed to assist you and your patients throughout the reimbursement process and beyond.

When therapy begins, NovoSecure™ assigns a dedicated NovoSecure™ Specialist to new patients to ensure proper paperwork and documentation are submitted, and to help you and your patients make the most of their treatment plan.

In addition, NovoSecure™ offers community-based resources to help patients and their families connect with caring, compassionate support, both locally and online.

Novo Nordisk takes great pride in its commitment to patients, and is pleased to offer services that support patients' ongoing treatment and their day-to-day lives with hemophilia.




**To get started or to speak with a
NovoSecure™ Specialist, contact
1-844-NOVO-SEC (1-844-668-6732).**





NovoSecure™ Reimbursement Support Process Flow



SMN=statement of medical necessity; PA=prior authorization; PAP=Product Assistance Program.

^aThe Interim Product Program is available for a limited duration to commercially insured patients with any of the 6 specific bleeding disorders. Patients who participate in Medicaid, Medicare (including Medicare Part D), or other federal or state health programs are not eligible for the Interim Product Program. Contact NovoSecure™ for complete eligibility requirements.

^bPatients who participate in Medicaid, Medicare (including Medicare Part D), or other federal or state health programs, or who are eligible or have a pending application for such plans, are not eligible for this program. Contact NovoSecure™ for complete eligibility requirements.



QuickCheck™

QuickCheck™ is a fast way to confirm insurance benefits before completing the Statement of Medical Necessity. Generally a **Summary of Benefits** will be provided within 4 hours, assuming all required information has been submitted. The following are the necessary steps.

- Obtain a QuickCheck™ form:
 - Contact your Novo Nordisk Hemophilia Therapy Manager, who can provide you with a QuickCheck™ pad
 - Online at mynovosecure.com
 - By phone at **1-844-NOVO-SEC (1-844-668-6732)**
 - Via email at mynovosecurespecialist@mynovosecure.com
- **IMPORTANT!** Complete all sections on the form; incomplete forms cannot be processed
- Fax the form to NovoSecure™ at **1-866-488-6576** or email it to mynovosecurespecialist@mynovosecure.com

Once the form is received:

- A NovoSecure™ Specialist will call the patient's insurance company to verify coverage
- Within **4 hours**, a Summary of Benefits will be faxed to the physician's office
- If the patient is not covered for any Novo Nordisk products, a list of alternate therapies on the patient's formulary will be provided

If the QuickCheck™ Form Is Not Completed...

Required information that is not provided is considered "missing information" and will delay the case moving forward. If this occurs, the physician's office will receive 2 notifications:

1 st Notification	2 nd Notification
Sent via method in which QuickCheck™ was received (fax or email)	Sent 48 hours later. If information is still not received, a closure notification will be sent. If received, Summary of Benefits will be provided



QuickCheck™

Novo Nordisk Hemophilia/RBD benefits verification in ~4 hours

= required field

NovoSecure™

Phone: 1-844-NOVO-SEC
(1-844-668-6732)

Fax: 1-866-488-6576

PATIENT INFORMATION	<p>First name Last name Birth date / / </p> <p>Street address City, State Zip </p>																
PRIMARY INSURANCE INFORMATION	<p>Please attach copies of both insurance cards and provide insurance information below. (required)</p> <p>Medical insurance company Member ID Group ID </p> <p>Cardholder name Relationship to cardholder </p> <p>Insurance phone () Bin # (if available) (if available)</p> <p>Medical group (IPA) </p> <p>Pharmacy benefit plan Member ID Group ID </p> <p>Insurance phone () Bin # (if available) (if available)</p> <p>Person code # PCN </p>																
DIAGNOSIS	<p>What is the primary diagnosis for which you are prescribing a Novo Nordisk factor product? (required)</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p><input type="checkbox"/> 286.0 (D66) Congenital hemophilia A (without inhibitors)</p> <p><input type="checkbox"/> 286.0 (D66) Congenital hemophilia A (with inhibitors)</p> <p><input type="checkbox"/> 286.1 (D67) Congenital hemophilia B (with inhibitors)</p> <p><input type="checkbox"/> 286.2 (D68.2) Other congenital factor deficiency (FVII)</p> </div> <div style="width: 48%;"> <p><input type="checkbox"/> 286.2 (D68.2) Other congenital factor deficiency (FXIII)</p> <p><input type="checkbox"/> 286.52 (D68.311) Acquired hemophilia</p> <p><input type="checkbox"/> 287.1 (D69.1) Qualitative platelet defect (Glanzmann's Thrombasthenia)</p> </div> </div>																
PRODUCT TO CHECK/ DOSING	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">Product name</th> <th style="width: 20%;">Dose</th> <th style="width: 30%;">Infusion instructions</th> <th style="width: 20%;">Quantity to dispense</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Do you intend to buy and bill? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>	Product name	Dose	Infusion instructions	Quantity to dispense												
Product name	Dose	Infusion instructions	Quantity to dispense														
																	
																	
																	
PHYSICIAN INFORMATION AND RELEASE	<p>I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. By my signature, I also acknowledge that I have obtained the patient's or guardian's authorization to release the above information and such other information as may be required for Novo Nordisk, its employees, or agents, including TMS Health (collectively, "NovoSecure™"), to assist in obtaining initial review of benefit coverage for specified Novo Nordisk factor product and to assist in initiating Novo Nordisk therapy.</p> <p>Health care professional signature Date NPI # Tax ID # </p> <p>Health care professional name (please print) Name of treatment center (if applicable) </p> <p>Address City, State Phone number </p> <p>Preferred mode of contact: <input type="checkbox"/> Email <input type="checkbox"/> Fax number <input type="checkbox"/></p> <p>Nurse or office contact name </p>																

NovoSecure™

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536 U.S.A.
NovoSecure™ and QuickCheck™ are trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2016 Novo Nordisk All rights reserved. USA16HDM04997 December 2016



NOTE: NovoSecure™ respects the confidentiality of patients' health information. All information included on this form will be routed securely through the mynovosecure.com website and used solely for the purposes of obtaining product coverage information.



Statement of Medical Necessity

Contact NovoSecure™ to obtain the appropriate SMN form by calling **1-844-NOVO-SEC (1-844-668-6732)**.

Fax the completed form to **1-866-488-6576**.

Required Information

Patient demographics	<ul style="list-style-type: none"> Includes contact information for family
Patient insurance	<ul style="list-style-type: none"> Allows NovoSecure™ to verify benefits if needed and submit for Prior Authorization (PA) process
Diagnosis	<ul style="list-style-type: none"> Allows NovoSecure™ to verify patient eligibility
Prescription	<ul style="list-style-type: none"> Needed for enrollment and identification of product
Services requested	<ul style="list-style-type: none"> Identifies services that physician has requested for patient
Medical assessment	<ul style="list-style-type: none"> Helps with PA and appeal process
Physician authorization	<ul style="list-style-type: none"> Attests that product is medically necessary for patient. Signature is required for enrollment and as part of prescription if separate prescription is not included

SMN missing information

Required information that is not provided is considered "missing information." Case cannot move forward until this is received.

Missing Information Procedure	1 st Notification	2 nd Notification	3 rd Notification
Physician's office	Fax or email submission: 5-day follow-up	Fax or email submission: 5-day follow-up	Fax or email submission: 5-day follow-up



Prior Authorizations

NovoSecure™ helps navigate the insurance process

- Identify payer coverage criteria specific to the diagnosis
- Gather all pertinent clinical information provided by physician's office
- Obtain and submit supporting documentation to insurance provider
- Follow up with determination outcomes

Based on the outcomes, NovoSecure™ also assists with next steps.



Approved:

- Specialty Pharmacy coordination
- Co-pay assistance coordination



Denied:

- Appeal (for eligible patients)
- Product Assistance Program (for eligible patients)



Supporting Documentation

The physician's office needs to send all pertinent information to obtain insurance coverage and a PA. Required supporting documentation may depend on the diagnosis. Below are the eligible diagnoses.

- ▶ Congenital hemophilia A
- ▶ Congenital hemophilia A or B with inhibitors
- ▶ Congenital factor VII deficiency
- ▶ Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- ▶ Acquired hemophilia
- ▶ Congenital factor XIII A-subunit deficiency



Appeals

How NovoSecure™ can help

If initial insurance claims are denied, NovoSecure™ will assist eligible patients through a multistep appeal process.

Physician Appeal

- ✓ NovoSecure™ Specialist (NSS) informs physician of payer-requested information and provides payer template letter if available
- ✓ Physician provides required information
- ✓ Physician submits to payer
- ✓ NSS follows up for determination

Patient Appeal

- ✓ NSS provides family with submission instructions
- ✓ Patient/caregiver submits directly to payer
- ✓ NSS follows up for determination

Appeal support is available only for commercially insured patients with specific bleeding disorders. Patients who participate in Medicaid, Medicare (including Medicare Part D), or other federal or state health care programs, or who are eligible or have a pending application for such plans, are not eligible for appeal support.



Co-pay Assistance Program

Eligible patients can receive up to **\$12,000** per year toward their co-pay for a Novo Nordisk product. Please visit mynovosecure.com/copay to access the application.

Patient Eligibility

- Patient has been prescribed a Novo Nordisk hemophilia product for an indicated condition
- Patient has private or commercial insurance

Terms and Conditions

Patients are not eligible if prescriptions are paid for by any state or federally funded programs, including, but not limited to, Medicare, Medicaid, Medigap, VA, DOD, or TRICARE, or where prohibited by law. Offer not valid for prescriptions reimbursed in full by any third-party payer. Offer limited to 1 card per person. Offer void where taxed, restricted, or prohibited. Offer only good in the United States. Eligibility is restricted to individuals; no clubs, groups, or organizations. The savings card is not transferable and is not insurance. By using the Novo Nordisk Hemophilia & Rare Bleeding Disorders Co-pay Assistance Card, patients are certifying that they understand the program rules, terms, and conditions and will comply with them. Offer excludes full cash-paying customers. Patients must be enrolled in a commercial insurance plan.



Product Assistance Program

Novo Nordisk's Product Assistance Program (PAP) supports uninsured patients with access to their hemophilia therapy at no cost for a limited time.

Eligible patients receive their hemophilia therapy for free. There is no registration charge or monthly fee for participating in the Novo Nordisk PAP.

Applications for this program can be downloaded at mynovosecure.com.

Patient Eligibility

- Patient is a US citizen or legal resident
- Patient has been prescribed a Novo Nordisk hemophilia product for an indicated condition
- Patient has no insurance coverage

Terms and Conditions

Patients who are eligible for Medicaid or Department of Veterans Affairs (VA) prescription benefits must have been denied enrollment, including exhaustion of all appeals, in order to be eligible for product assistance. Uninsured patients who have opted not to obtain coverage through the Affordable Care Act's health insurance marketplace are eligible for PAP for the resolution of the current bleed if they have committed to enrolling in the health care marketplace during the next open enrollment period. The number of doses provided varies between Novo Nordisk products. Please contact your NovoSecure™ Specialist for more information.



Interim Product Program

Eligible patients with unresolved insurance reimbursement issues can receive their hemophilia therapy free of charge for a limited duration through the Interim Product Program.^a This program is available only for commercially insured patients and is used to prevent treatment gaps due to appeals, reauthorizations, changes in coverage, and other situations.

Patient eligibility

- Requires current (less than 90 days old) valid prescription and documentation of diagnosis
- Requests must be made through SMN submission to NovoSecure™



Jay lives with severe hemophilia B with inhibitors.

^aPatients who participate in Medicaid, Medicare (including Medicare Part D), or other federal or state health programs, or who are eligible or have a pending application for such plans, are not eligible for the Interim Product Program.



Patient Reauthorization



NovoSecure™ assists patients throughout the reauthorization process, as directed by physicians' offices, by:

- Faxing a reauthorization notice with SMN to the physician's office 15 days before expiration
- Requesting an updated SMN and clinical data necessary for reauthorization
- Forwarding the information to the appropriate party and following up to obtain the reauthorization decision



If the reauthorization is handled by the pharmacy or physician's office, NovoSecure™ may provide confirmation of reauthorization approval with the office and payer.

Phone Support



After therapy has begun, NovoSecure™ Specialists will continue to support patients by phone. Patients can call: 1-844-NOVO-SEC (1-844-668-6732) for:

- Information on managing bleeding disorders
- Answers to insurance questions
- Help with product assistance applications



Helping Patients Manage Their Lives With Hemophilia

NovoSecure™ provides these free tools and resources to patients when they register at mynovosecure.com.

HemaGo™ App

- ✓ **The HemaGo™ app enables patients to manage details about treatments, bleeds, and more from a desktop or mobile device, including:**
 - Tracking treatments and adding reasons for infusions
 - Recording type, location, duration, frequency, and status of bleeds
 - Setting treatment reminders
 - Getting in-depth reports for all recorded information
 - Sharing information with health care providers
 - Generating reports in PDF or email form and sending them directly to physicians
 - Sharing information with health care providers through HemaGo™ XChange
 - Doctors, nurses, and pharmacists can register at hgxchange.com to get real-time access to patients' shared bleed and infusion logs
 - Patients can also share their logs with the American Thrombosis and Hemostasis Network (ATHN), a nonprofit organization that uses real patient data to study treatment and develop new standards of care



United in Strength™

- ✓ **United in Strength™ offers inspiration and resources to address the unique needs and concerns of those with bleeding disorders in the Latino community.**

Community University

- ✓ **Community University is a series of engaging and informative workshops for patients with a bleeding disorder and their caregivers and loved ones. Each interactive workshop enables participants to connect with others while learning practical information for living well with hemophilia. Topics include pain management, food and fitness, caregiver coping skills, and more.**

Taller Hemofilia

- ✓ **Learn about educational topics for the Latino community, delivered in Spanish. It's a free series of fun and interactive workshops that provide opportunities for you to connect with others and learn practical tips and information about living well with hemophilia.**



Fostering Personal and Professional Growth

HeroPath™



- ✓ HeroPath™ is a year-long program designed to provide teens and young adults with the tools they need to identify:
 - Professional career paths based on interests, strengths, and talents
 - Personal and professional challenges and opportunities
 - The kind of person they want to be
- ✓ Patients can apply for the HeroPath™ program if they are between the ages of 16 and 34, are legal residents of the United States, are privately insured or uninsured, and meet other eligibility requirements.

Competitive College Scholarships

- ✓ Novo Nordisk offers the opportunity for students with bleeding disorders, regardless of treatment choice, to compete for scholarships to help them achieve their educational goals. Eligible students can apply for one of four \$5000 4-year college scholarships or ten \$2500 community or vocational scholarships.



Helping Patients Connect

NovoSecure™

✓ **NovoSecure™ offers patients numerous ways to stay informed and connect with those in the bleeding disorder community.**

- Changing Hemophilia™ on Facebook
- Links to local foundation chapters
 - Hemophilia Federation of America
 - National Hemophilia Foundation
 - Glanzmann's Research Foundation
- Links to national foundation blogs
 - Hemophilia Federation of America (HFA) news and stories
 - National Hemophilia Foundation HemAware magazine and blogs

NovoSecure™

Victor lives with hemophilia A.

NovoSecure™ — Here to help at every step of the journey


NovoSecure™ offers a full range of services to help you and your patients with hemophilia or rare bleeding disorders make the most of their treatment plan, including:

- ✓ Insurance coordination prior to therapy
- ✓ Product assistance for eligible patients
- ✓ Interim product program
- ✓ Ongoing support for patients

Contact NovoSecure™ Today

 **1-844-NOVO-SEC**
(1-844-668-6732)

 **mynovosecure.com**

NovoSecure™, Changing Hemophilia™, QuickCheck™, HemaGo™, and United in Strength™ are trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
 printed on recycled paper
© 2017 Novo Nordisk Printed in the U.S.A.
USA16HDM05058 January 2017

NovoSecure™




novo nordisk®